Fingerprint
Dive into the research topics of 'Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
Philippe Armand, Pierluigi Luigi Zinzani, Hun Ju Lee, Nathalie A Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A Shipp, Alex F Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H Moskowitz
- Dana-Farber Cancer Institute
- Universita Degli Studi Bologna
- University of Texas MD Anderson Cancer Center
- Jewish General Hospital
- AP-HP Hôpital Saint-Louis
- Institut de Cancerlogie Gustave Roussy
- Uppsala University Hospital
- National and Kapodistrian University of Athens
- Nagoya University
- Fachhochschule Koln - Cologne University of Applied Sciences
- City of Hope National Medical Center
- Merck Frosst Canada Ltd
- University of Miami
Research output: Contribution to journal › Article › peer-review